Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:31:05.194Z.
Calculation as of: 2026-10-06T16:31:05.194Z.
Quote observation: 2026-10-06T16:30:28.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 92e82853ec35d591c91e1857ba5f245e9338475f566e1ab86be3b7c1b83139db
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Artiva Biotherapeutics, Inc.
Market Cap
$354.70M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$355.36M
EV/EBIT Ratio
N/A
TTM Avg
55.83x
3Y Avg
55.83x
5Y Avg
55.83x
Market Cap
$349.40M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$359.33M
EV/EBIT Ratio
N/A
TTM Avg
45.54x
3Y Avg
33.14x
5Y Avg
24.49x
Market Cap
$374.75M
EV/EBIT Ratio
N/A
TTM Avg
1178.46x
3Y Avg
1178.46x
5Y Avg
1178.46x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | $354.70M | N/A | N/A | N/A | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $355.36M | N/A | 55.83x | 55.83x | 55.83x |
| Relmada Therapeutics, Inc. (RLMD)vs › | $353.30M | N/A | N/A | N/A | N/A |
| Ocugen, Inc. (OCGN)vs › | $359.46M | N/A | N/A | N/A | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.40M | N/A | N/A | N/A | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $359.33M | N/A | 45.54x | 33.14x | 24.49x |
| Embecta Corp. (EMBC)vs › | $359.53M | 6.51x | 5.53x | 9.02x | 8.48x |
| Opus Genetics, Inc. (IRD)vs › | $363.54M | N/A | N/A | N/A | N/A |
| Canopy Growth Corporation (CGC)vs › | $374.75M | N/A | 1178.46x | 1178.46x | 1178.46x |
| Agenus Inc. (AGEN)vs › | $333.02M | 9.81x | 35.72x | 35.72x | 18.31x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
